Jay Koyner
Section of Nephrology
Associate Professor of Medicine
Referring Physician Access Line: 1-877-DOM-2730


BA1996Johns Hopkins UniversityBiophysics
MD2001State University of New YorkMedicine
Residency2004The University of Chicago Medical CenterInternal Medicine
Fellowship2007The University of Chicago Medical CenterNephrology

Academic Interests

Dr. Koyner has a clinical research focus in Critical Care Nephrology. His research group’s primary focus is on the diagnosis, care and treatment patient’s of acute kidney injury (AKI). AKI is an all too common occurrence in hospitalized patients, especially in the setting of critical illness / intensive care unit setting where despite the tremendous advances in understanding renal disease at the physiologic and molecular level it still carries an alarmingly high morbidity and mortality. As such, one of the group’s main projects is to better characterize the definition of AKI through the evaluation and investigation of a variety of novel plasma and urinary biomarkers of kidney injury in a variety of clinical settings. These studies will evaluate the biomarkers ability to provide not only an earlier diagnosis of AKI (compared to the current gold standard, serum creatinine) but also prognosticate the severity of the disease, as well as better define who is at greatest risk for long-term adverse (renal and non-renal) events. Similarly, Dr Koyner is involved in projects that explore potential prophylactic and therapeutic treatments for AKI in a variety of setting of critical illness (performed in collaboration with investigators from Pulmonary and Critical Care Medicine and Anesthesia Critical Care). As director of UCMC’s Inpatient Renal Replacement Therapy (RRT) Unit, he is performing studies investigating the optimal delivery of continuous RRT (CRRT) in the setting of the most severe forms of AKI. These studies include the examination of drug utilization and dosing in the setting of CRRT.

Clinical Interests

Acute kidney injury, critical care nephrology, chronic kidney disease

Representative Publications

  1. Haase M, Devarajan P, Haase Fileitz A, Bellomo R, Wagener G, Koyner J, Murray PT, Ware K, Ikilizer I et al.The Outcome of Neutrophil Gelatinase-Associated Lipocalin (NGAL) positive Subclinical Acute Kidney Injury: A Multicenter Pooled Analysis of Prospective Studies Journal of the American College of Cardiology. In press Accepted November 2010.
  2. Koyner JL, Vaidya VS, Bennet M, Ma Q, Worcester EM, Akther SA, Raman J, Jeevanandam V, O’Connor MF, Devarajan P, Bonventre JV and Murray PT. Urinary Biomarkers in the Clinical Prognosis and Early Detection of Acute Kidney Injury. (2010) Clinical Journal of American Society of Nephrology ePublished August 26, 2010
  3. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A; NGAL Meta-analysis Investigator Group Accuracy of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Diagnosis and Prognosis in Acute Kidney Injury: A Systematic Review and Meta-analysis. (2009) Am J Kidney Dis. Dec;54(6):1012-24
  4. Lu JC, Coca SG, Patel UD, Cantley L, Parikh CR; Translational Research Investigating Biomarkers and Endpoints for Acute Kidney Injury (TRIBE-AKI) Consortium. Searching for genes that matter in acute kidney injury: a systematic review. (2009) Clin J Am Soc Nephrol. Jun;4(6):1020-31.
  5. Koyner JL, Bennett, M Worcester E, Ma, Q Raman J, Jeeaenandam V, Kasza KE, O’Connor MF, Trevino S, Devarajan, P and Murray PT. (2008) Urinary Cystatin C: A Novel Early Biomarker of AKI Development and Severity after Adult Cardiothoracic Surgery. Kidney Int. Oct;74(8):1059-69. Epub 2008 Jul 23.

More Information

For more information about Dr. Jay Koyner publications and research collaborations , please click here